Facing declining revenue from blockbuster products like Keytruda and Gardasil, Merck announced an ambitious $3 billion annual cost-saving program to be completed by 2027. The initiative includes eliminating administrative, sales, and R&D positions while investing these savings into newer product launches and experimental medicines across oncology and cardiometabolic indications. The company is realigning its global real estate and manufacturing footprint to better reflect business needs. This transformation aims to support growth in next-generation drugs amid increasing biosimilar competition and market challenges in its established portfolio.